227 abstracts found.



Results filter



Introduction: immunotherapy

Year:

Session type: ,




Introduction: molecular imaging and radionuclide therapy: The Royal College of Radiologists symposium

Year:

Session type: ,




Introduction: lifestyle behaviour and prevention

Year:

Session type: ,




Introduction: genomics and cancer evolution

Year:

Session type: ,




Introduction: DNA repair and cancer

Year:

Session type: ,




Introduction: big data

Year:

Session type: ,




Introduction: molecular testing for early cancer diagnosis: ready for prime time

Year:

Session type: ,




Introduction: chromatin, epigenetics and cancer

Year:

Session type: ,




The mechanistic basis of cancer immunotherapy

Year:

Session type: ,

Ira Mellman1

1Genentech, South San Francisco, USA




Benchmarking and biomarkers: the molecular and technical heterogeneity of prostate cancer

Year:

Session type: ,

Paul Boutros1

1Ontario Institute for Cancer Research, Toronto, Canada




Epigenetics impacts copy number heterogeneity and drug resistant gene selection

Year:

Session type: ,

Johnathan Whetstine1

1Harvard Medical School & Massachusetts General Hospital Cancer Center, Boston, USA




T cells and the immunogenicity of immunotherapy

Year:

Session type: ,

Adrian Hayday1

1King’s College London & The francis Crick Institute, London, UK




Genetic dissection of tumor development, therapy response and resistance in mouse models of BRCA1-deficient breast cancer

Year:

Session type: ,

Jos Jonkers1

1Netherlands Cancer Institute, Amsterdam, The Netherlands




Radium-223 for prostate cancer bone metastases: How research can change clinical practice

Year:

Session type: ,

Joe O’Sullivan1,2

1Queen’s University Belfast, Belfast, Northern Ireland, UK,2Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK




Molecularly Targeted Radiation Therapy: Towards Individualised Treatment 

Year:

Session type: ,

Katherine Vallis1

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK




Molecular biomarkers: are they so much better than traditional risk factors and simple biomarkers?

Year:

Session type: ,

Peter Sasieni1

1Queen Mary University of London, London, UK




Gut microbiota and anti-cancer immune responses 

Year:

Session type: ,

Laurence Zitvogel1

1Institut Gustave Roussy and INSERM, Villejuif, France




Epigenetic Targets for Cancer Drug Discovery: Bromodomains and Beyond

Year:

Session type: ,

Mark Bunnage1

1Pfizer, Cambridge, MA, USA




Evolution and drug resistance in cancer.

Year:

Session type: ,

Ultan McDermott1

1Wellcome Trust Sanger Institute, Hinxton, UK




Translating novel diagnostic and therapeutic radiopharmaceuticals into the clinic”

Year:

Session type: ,

Wim Oyen1,2

1The Institute of Cancer Research, London, UK,2The Royal Marsden NHS Foundation Trust, London, UK




Tracking tumour evolution with clonal assays – mutation order matters.

Year:

Session type: ,

David Kent1,2

1Wellcome Trust/ MRC Cambridge Stem Cell Institute, Cambridge, UK,2Department of Haematology University of Cambridge, Cambridge, UK




Epigenetic reprogramming in mammalian development

Year:

Session type: ,

Wolf Reik1

1Babraham Institute, Cambridge, UK,2Centre for Trophoblast Research, University of Cambridge, Cambridge, UK,3Wellcome Trust Sanger Institute, Cambridge, UK




Devising the ideal test for early diagnosis of cancer: lessons from the oesophagus

Year:

Session type: ,

Rebecca Fitzgerald1

1Univeristy of Cambridge, Cambridge, UK




Working together in the Genomics Era – Lessons from the GTEOC study 

Year:

Session type: ,

Marc Tischkowitz1

1University of Cambridge, Cambridge, UK




Reducing exposure to alcohol to reduce cancer risk.

Year:

Session type: ,

Peter Anderson1

1Newcastle University, Newcastle, UK




Understanding genome organisation: using HiC data to interpret gene regulation and non-coding mutations

Year:

Session type: ,

Nicholas Luscombe1

1The Francis Crick Institute, London, UK




How many cancers can we prevent through dietary modifications?

Year:

Session type: ,

Paolo Boffetta1

1Icahn School of Medicine at Mount Sinai, New York NY, USA




Role of the BRCA1:BARD1 Ubiquitin Ligase Activity in DNA repair.

Year:

Session type: ,

Jo Morris1

1University of Birmingham, West Midlands, UK




Physical activity, obesity and cancer

Year:

Session type: ,

Martin Wiseman1,2

1WCRF International, London, UK,2University of Southampton, Southampton, UK




Protective packaging for DNA: the role of the PBAF and INO80 chromatin remodelling complexes in maintaining genome stability

Year:

Session type: ,

Jessica Downs1

1Genome Damage and Stability Centre, Falmer, Brighton, UK




Phylogenetic analysis reveals divergent modes of clonal spread and intraperitoneal mixing in high grade serous ovarian cancer

Year:

Session type: ,

Sohrab Shah1,2

1BC Cancer Agency Research Centre, Vancouver, BC, Canada,2University of British Columbia, Vancouver, BC, Canada




Introduction: Stratified medicine

Year:

Session type:

Alan Ashworth1
1The Institute of Cancer Research, London, UK



Post-translational chemokine modification prevents intratumoral infiltration of antigen-specific T cells

Year:

Session type:

Vincenzo Bronte1
1Verona University, Verona, Italy



HDAC inhibitors: From bench to clinic, and back again

Year:

Session type:

Nicholas La Thangue1
1University of Oxford, Oxford, UK



Epigenetic plasticity and the basis of human cancer

Year:

Session type:

Andrew Feinberg1
1Johns Hopkins University, Baltimore, MD, USA



Introduction: Predictive mouse models of human cancer

Year:

Session type:

David Tuveson1
1Cancer Research UK, Cambridge, UK



Can genetic risk profiling in colorectal cancer guide prevention and screening?

Year:

Session type:

Malcolm Dunlop1
1University of Edinburgh, Edinburgh, UK



Harnessing transposons for cancer gene discovery

Year:

Session type:

Neal Copeland1
1Institute of Molecular and Cell Biology, Singapore, Singapore



Introduction: EMT in cancer, development and tissue maintenance

Year:

Session type:

Nick Hastie1
1MRC Human Genetics Unit, Edinburgh, UK



Studying therapy response and resistance in mouse models of human breast cancer

Year:

Session type:

Jos Jonkers1
1Netherlands Cancer Institute, Amsterdam, The Netherlands



MicroRNAs, EMT and cancer stem cells

Year:

Session type:

Thomas Brabletz1
1University of Freiburg, Freiburg, Germany



Modelling and targeting differentiation-state heterogeneity in cancer

Year:

Session type:

Piyush Gupta1
1Whitehead Institute for Biomedical Research, Cambridge, MA, USA



Intravital imaging of metastasis

Year:

Session type:

Erik Sahai1
1Cancer Research UK London Research Institute, London, UK



Introduction: Metabolism and cancer

Year:

Session type:

Eyal Gottlieb1
1Beatson Institute for Cancer Research, Glasgow, UK



Metabolic alterations to support cancer cell proliferation

Year:

Session type:

Matthew Vander Heiden1
1Koch Institute at MIT, Cambridge, MA, USA



Predicting selective drug targets in cancer through metabolic networks

Year:

Session type:

Tomer Shlomi1
1Technion, Haifa, Israel



Imaging tumour metabolism using hyperpolarised 13C magnetic resonance spectroscopy

Year:

Session type:

Kevin Brindle1
1University of Cambridge, Cambridge, UK



Introduction: The diagnostic and therapeutic potential of the tumour microenvironment

Year:

Session type:

Thorsten Hagemann1
1Barts Cancer Institute, London, UK



Human cancer epigenetics

Year:

Session type:

Manel Esteller1
IDIBELLBellvitge Biomedical Research Institute



Modelling the role of the tumour microenvironment in therapeutic response

Year:

Session type:

Michael Hemann1
1MIT, Cambridge, MA, USA